Cellular Biomedicine Group (CBMG) and GE Healthcare Life Sciences China Announce Strategic Partnership to Establish Joint Technology Laboratory to Develop Control Processes for the Manufacture of CAR-T and Stem Cell Therapies
10 avr. 2017 08h04 HE
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., April 10, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (CBMG or the Company), a leading clinical-stage biopharmaceutical firm engaged...
Cellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CARD-1) for C-CAR011 in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL) in China
29 nov. 2016 07h16 HE
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biomedicine firm engaged in the...
Cellular Biomedicine Group to Present at the 2016 World Stem Cell Summit
28 nov. 2016 07h36 HE
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biomedicine firm engaged in the...
Cellular Biomedicine Group Announces Dismissal of Class Action Litigation
18 août 2016 07h09 HE
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biomedicine firm engaged in the...
UPDATE -- Cellular Biomedicine Group Reports Second Quarter and First Half 2016 Financial Results and Business Highlights
09 août 2016 09h36 HE
|
Cellular Biomedicine Group Inc.
- Ended Second Quarter with $47.5 million in Cash - SHANGHAI, China and CUPERTINO, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the...
Cellular Biomedicine Group Reports Second Quarter and First Half 2016 Financial Results and Business Highlights
09 août 2016 06h25 HE
|
Cellular Biomedicine Group Inc.
- Ended Second Quarter with $47.5 million in Cash - SHANGHAI, China and CUPERTINO, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the...
Cellular Biomedicine Group Announces Annual General Meeting of Stockholders
01 août 2016 08h30 HE
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biomedicine firm engaged in the...
Cellular Biomedicine Group Reports First Quarter 2016 Financial Results and Provides Business Highlights
09 mai 2016 16h01 HE
|
Cellular Biomedicine Group Inc.
– Reported Positive Clinical Data from Phase IIb trial of ReJoin® haMPC therapy– Expanded Stem Cell Platform with the Launch of New Allogeneic Clinical Trial– Closed Strategic Investment of $43.13...
Cellular Biomedicine Group Announces Closing of $43.13 Million Strategic Investment from Dangdai International Group Co., Limited, a Wholly-Owned Hong Kong Subsidiary of Wuhan Dangdai Science & Technology Industries Group Inc.
19 avr. 2016 08h30 HE
|
Cellular Biomedicine Group Inc.
SHANGHAI, China and CUPERTINO, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biomedicine...
Cellular Biomedicine Group Reports Full-Year 2015 Financial Results and Recent Operational Progress
14 mars 2016 07h00 HE
|
Cellular Biomedicine Group Inc.
- Achieved first clinical milestones for CD19, CD20, CD30 and EGFR CAR-T cell assets- Expanded Immuno-Oncology platform with key acquisitions- Expanded Stem Cell platform with the launch of new...